Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

Expected to succeed Dr. Ulrich Kostlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its Board of Directors, effective following completion of this year's ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a ...

a target that already features in approved therapies for myeloma, including GlaxoSmithKline's first-to-market antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin). Since Blenrep made its ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Ladenburg, Germany, 21 March 2025 – Heidelberg Pharma AG (FSE: HPHA) today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024) and its outlook ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.